PDCD1 and hepatocellular carcinoma: In 2020, the Food and Drug Administration approved ICB as additional systemic therapies [Nivolumab and Pembrolizumab for programmed cell death protein 1 (PD-1) blockades; ipilimumab for cytotoxic T lymphocytes antigen-4 (CTLA-4)] for advanced HCC.